AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1000996 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral non-dominant temporo-parietal ECT
Number of subjects: 0
Study 1000996 — intervention group
Group type: COMPARATOR
Intervention: Unilateral dominant temporo-parietal ECT
Number of subjects: 0
Study 1000996 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral non-dominant fronto-frontal ECT
Number of subjects: 0
Study 31905607 — intervention group
Group type: EXPERIMENTAL
Intervention: 40-g protein drink
Number of subjects: 12
Study 31905607 — intervention group
Group type: EXPERIMENTAL
Intervention: isocaloric maltodextrin drink
Number of subjects: 12
Study 31905607 — intervention group
Group type: COMPARATOR
Intervention: placebo water control
Number of subjects: 12
Study 29195547 — intervention group
Group type: EXPERIMENTAL
Intervention: Long RV-LV interval group (≥67 ms)
Number of subjects: 1342
Study 29195547 — intervention group
Group type: EXPERIMENTAL
Intervention: RV-LV time as a continuous variable
Number of subjects: 1342
Study 25322870 — intervention group
Group type: EXPERIMENTAL
Intervention: Workplace intervention programme tailored according to functional ability and workplace challenges
Number of subjects: 80
Study 25322870 — intervention group
Group type: COMPARATOR
Intervention: Usual stroke care without workplace intervention
Number of subjects: 80
Study 25322870 — intervention group
Group type: EXPERIMENTAL
Intervention: Workplace intervention programme
Number of subjects: 80
Study 25322870 — intervention group
Group type: EXPERIMENTAL
Intervention: Activities of daily living (ADLs) and cognitive assessment
Number of subjects: 80
Study 25322870 — intervention group
Group type: EXPERIMENTAL
Intervention: Return to work
Number of subjects: 80
Study 22911624 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate (400 mg/day) plus UDCA (600 mg/day) for 3 months
Number of subjects: 19
Study 22911624 — intervention group
Group type: COMPARATOR
Intervention: UDCA (600 mg/day) monotherapy
Number of subjects: 19
Study 21562081 — intervention group
Group type: EXPERIMENTAL
Intervention: Active video game upgrade package (n = 160)
Number of subjects: 322
Study 21562081 — intervention group
Group type: COMPARATOR
Intervention: Control group (no change, n = 162)
Number of subjects: 322
Study 18989547 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Mandatory Ventilation (IMV)
Number of subjects: 70
Study 18989547 — intervention group
Group type: COMPARATOR
Intervention: Synchronized Intermittent Mandatory Ventilation plus Pressure Support (SIMV+PS)
Number of subjects: 70
Study 17229660 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% of total daily insulin requirement
Number of subjects: 75
Study 17229660 — intervention group
Group type: EXPERIMENTAL
Intervention: 60% of total daily insulin requirement
Number of subjects: 75
Study 17229660 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% of total daily insulin requirement
Number of subjects: 75
Study 12620944 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg
Number of subjects: 168
Study 12620944 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 168
Study 10877616 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe preeclampsia
Number of subjects: 16
Study 10877616 — intervention group
Group type: COMPARATOR
Intervention: Normotensive pregnant women
Number of subjects: 16
Study 9311219 — intervention group
Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia with propofol and fentanyl
Number of subjects: 40
Study 9311219 — intervention group
Group type: COMPARATOR
Intervention: Inhalational anesthesia with nitrous oxide and isoflurane
Number of subjects: 40
Study 7953033 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based care (DLPII, n = 33)
Number of subjects: 66
Study 7953033 — intervention group
Group type: COMPARATOR
Intervention: Out-/in-patient care (DLP-control, n = 33)
Number of subjects: 66
Study 7953033 — intervention group
Group type: COMPARATOR
Intervention: Phase I controls (n = 70)
Number of subjects: 66
Study 7953033 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based care (DLPII) and Out-/in-patient care (DLP-control)
Number of subjects: 66
Study 3234467 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20‐40 mg/day
Number of subjects: 16
Study 3234467 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate 600 mg/day
Number of subjects: 16
Study 31411528 — intervention group
Group type: EXPERIMENTAL
Intervention: 1540-nm nonablative fractional erbium laser
Number of subjects: 15
Study 28879629 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping Effectiveness Training (CET) intervention
Number of subjects: 28
Study 28879629 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 28
Study 29199898 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss-framed first-person narrative
Number of subjects: 461
Study 29199898 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain-framed first-person narrative
Number of subjects: 461
Study 26210120 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-operative caries treatment programme (NOCTP)
Number of subjects: 230
Study 26210120 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical fluoride applications (IPFA)
Number of subjects: 230
Study 26210120 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard prevention)
Number of subjects: 230
Study 24095892 — intervention group
Group type: COMPARATOR
Intervention: Direct Laryngoscopy (DL)
Number of subjects: 34
Study 24095892 — intervention group
Group type: COMPARATOR
Intervention: GlideScope Videolaryngoscopy (GVL)
Number of subjects: 34
Study 24095892 — intervention group
Group type: EXPERIMENTAL
Intervention: GlideScope Groove (GG)
Number of subjects: 34
Study 21522073 — intervention group
Group type: EXPERIMENTAL
Intervention: Speed, Agility, Quickness (SAQ) training method
Number of subjects: 100
Study 18205978 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone (Meth)
Number of subjects: 140
Study 18205978 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (Bup)
Number of subjects: 140
Study 18205978 — intervention group
Group type: COMPARATOR
Intervention: Both Meth and Bup
Number of subjects: 140
Study 16861095 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam 1,500 mg IV infusion
Number of subjects: 18
Study 16861095 — intervention group
Group type: COMPARATOR
Intervention: Levetiracetam 500 mg oral tablets
Number of subjects: 18
Study 16861095 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam 1,500 mg IV infusion (multiple doses)
Number of subjects: 18
Study 16861095 — intervention group
Group type: COMPARATOR
Intervention: Placebo (multiple doses)
Number of subjects: 18
Study 12646326 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine Maintenance (21 mg transdermal nicotine for 8 weeks)
Number of subjects: 55
Study 12646326 — intervention group
Group type: COMPARATOR
Intervention: Standard Treatment (tapered dosing regimen)
Number of subjects: 55
Study 12646326 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine Maintenance
Number of subjects: 55
Study 10844068 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate (Viagra)
Number of subjects: 0
Study 9412274 — intervention group
Group type: COMPARATOR
Intervention: Intravenous PCA (PCA-i.v.)
Number of subjects: 40
Study 9412274 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural PCA (PCA-PDK)
Number of subjects: 40
Study 8449067 — intervention group
Group type: COMPARATOR
Intervention: Bambuterol 10 mg
Number of subjects: 0
Study 8449067 — intervention group
Group type: COMPARATOR
Intervention: Bambuterol 20 mg
Number of subjects: 0
Study 8449067 — intervention group
Group type: COMPARATOR
Intervention: Bambuterol 5 mg
Number of subjects: 0
Study 8449067 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 0
Study 3994163 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 ppm sulfur dioxide in filtered air
Number of subjects: 19
Study 3994163 — intervention group
Group type: COMPARATOR
Intervention: Filtered air alone
Number of subjects: 19
Study 30099726 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week stress management intervention program (progressive muscle relaxation, diaphragmatic breathing, guided imagery, cognitive restructuring)
Number of subjects: 36
Study 30099726 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week stress management intervention program
Number of subjects: 36
Study 30099726 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study 26874892 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-directed exercise intervention
Number of subjects: 312
Study 26874892 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-directed nutrition intervention
Number of subjects: 312
Study 26874892 — intervention group
Group type: EXPERIMENTAL
Intervention: Leisure-time physical activity (≥2 hours)
Number of subjects: 312
Study 24925584 — intervention group
Group type: EXPERIMENTAL
Intervention: Novolin® 30R (initial dose 0.5 IU/kg)
Number of subjects: 188
Study 24925584 — intervention group
Group type: COMPARATOR
Intervention: Lantus® combined with acarbose (Glucobay®) (initial dose 0.2 IU/kg and 50 mg acarbose)
Number of subjects: 188
Study 23684862 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 32
Study 23684862 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 21966941 — intervention group
Group type: COMPARATOR
Intervention: TACE alone (group 1)
Number of subjects: 34
Study 21966941 — intervention group
Group type: EXPERIMENTAL
Intervention: MWA after TACE (group 2)
Number of subjects: 34
Study 18436050 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial calls to ED referral numbers
Number of subjects: 603
Study 18436050 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful appointment attempts
Number of subjects: 603
Study 18436050 — intervention group
Group type: EXPERIMENTAL
Intervention: Hold time for callers
Number of subjects: 603
Study 18436050 — intervention group
Group type: EXPERIMENTAL
Intervention: Total telephone time for successful appointments
Number of subjects: 603
Study 18436050 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of calls to reach appointment staff
Number of subjects: 603
Study 16897026 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial quality of care by physicians
Number of subjects: 90
Study 16897026 — intervention group
Group type: EXPERIMENTAL
Intervention: Active integration in treatment decisions
Number of subjects: 90
Study 12534411 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole (10 mg b.d.) + Amoxicillin (750 mg b.d.) + Clarithromycin (400 mg b.d.)
Number of subjects: 187
Study 12534411 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole (30 mg b.d.) + Amoxicillin (750 mg b.d.) + Clarithromycin (400 mg b.d.)
Number of subjects: 187
Study 12534411 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin-sensitive strains
Number of subjects: 187
Study 12534411 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin-resistant strains
Number of subjects: 187
Study 12534411 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensive metabolizers in RAC group
Number of subjects: 187
Study 12534411 — intervention group
Group type: COMPARATOR
Intervention: Extensive metabolizers in LAC group
Number of subjects: 187
Study 10497402 — intervention group
Group type: EXPERIMENTAL
Intervention: Step‐by‐step pharmacologic therapy including bronchodilators (beta 2‐agonists, anticholinergic agents), theophylline, and oral corticosteroids
Number of subjects: 0
Study 10497402 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids
Number of subjects: 0
Study 8762348 — intervention group
Group type: EXPERIMENTAL
Intervention: Contaminated water consumption
Number of subjects: 3861
Study 1849810 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin 20 mg single oral dose
Number of subjects: 8
Study 1849810 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin 20 to 40 mg twice daily for 4 weeks
Number of subjects: 8
Study 1849810 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 1849810 — intervention group
Group type: EXPERIMENTAL
Intervention: Serotonin 1 ng/kg/min
Number of subjects: 8
Study 1849810 — intervention group
Group type: EXPERIMENTAL
Intervention: Serotonin highest dose
Number of subjects: 8
Study 1849810 — intervention group
Group type: EXPERIMENTAL
Intervention: Methoxamine
Number of subjects: 8
Study 7000631 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE2 (1 mg four times daily)
Number of subjects: 27
Study 7000631 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE2 (1 mg four times daily) with ASA (600 mg four times daily)
Number of subjects: 27
Study 7000631 — intervention group
Group type: COMPARATOR
Intervention: ASA (600 mg four times daily)
Number of subjects: 27
Study 31152605 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (1.2 mg/kg every 2 weeks)
Number of subjects: 0
Study 31152605 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Number of subjects: 0
Study 28067718 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP-IPV//Hib booster vaccine administered concomitantly with CYD-TDV
Number of subjects: 732
Study 28067718 — intervention group
Group type: COMPARATOR
Intervention: CYD-TDV administered as a 3-dose schedule
Number of subjects: 732
Study 28067718 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety assessment of both vaccines
Number of subjects: 732
Study 25886748 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% xenon as an adjuvant to sevoflurane anaesthesia
Number of subjects: 40
Study 25886748 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane alone
Number of subjects: 40
Study 23539078 — intervention group
Group type: EXPERIMENTAL
Intervention: Different devices for shoulder extensions at xiphoid process depth
Number of subjects: 24
Study 23539078 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoulder extensions at xiphoid process depth
Number of subjects: 24
Study 23539078 — intervention group
Group type: COMPARATOR
Intervention: Shoulder extensions at clavicle depth
Number of subjects: 24
Study 21276644 — intervention group
Group type: EXPERIMENTAL
Intervention: High calcium trial (HCT)
Number of subjects: 11
Study 21276644 — intervention group
Group type: COMPARATOR
Intervention: Low calcium trial (LCT)
Number of subjects: 11
Study 19682114 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention (hour-long classes 3 days per week for 24 weeks)
Number of subjects: 118
Study 19682114 — intervention group
Group type: COMPARATOR
Intervention: Control group (monthly luncheon and seminar, mailings)
Number of subjects: 118
Study 17289744 — intervention group
Group type: EXPERIMENTAL
Intervention: Top quartile of systolic blood pressure (SBP) > 140 mmHg
Number of subjects: 7330
Study 17289744 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean systolic BP > or = 140 mmHg
Number of subjects: 7330
Study 17289744 — intervention group
Group type: COMPARATOR
Intervention: Quartiles of blood pressure (BP)
Number of subjects: 7330
Study 14984381 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha plus amantadine (200 mg/day)
Number of subjects: 181
Study 14984381 — intervention group
Group type: COMPARATOR
Intervention: Interferon-alpha alone
Number of subjects: 181
Study 11375883 — intervention group
Group type: EXPERIMENTAL
Intervention: Nirschl tennis elbow release with drilling
Number of subjects: 0
Study 11375883 — intervention group
Group type: COMPARATOR
Intervention: Nirschl tennis elbow release without drilling
Number of subjects: 0
Study 9207314 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and gemcitabine combination
Number of subjects: 0
Study 9207314 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin/ifosfamide/cisplatin (MIC) regimen
Number of subjects: 0
Study 9207314 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin/etoposide (PE)
Number of subjects: 0
Study 9207314 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive care plus cisplatin-based chemotherapy
Number of subjects: 0
Study 7970447 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardioscint non-imaging nuclear probe system
Number of subjects: 40
Study 2442788 — intervention group
Group type: EXPERIMENTAL
Intervention: Reserpine 5 mg IM b.i.d. over 2 days (placebo-controlled, double-blind trial)
Number of subjects: 8
Study 2442788 — intervention group
Group type: COMPARATOR
Intervention: Desipramine (DMI) treatment
Number of subjects: 8
Study 2442788 — intervention group
Group type: EXPERIMENTAL
Intervention: Reserpine augmentation
Number of subjects: 8
Study 31888783 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine rinse
Number of subjects: 490
Study 31888783 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine rinse
Number of subjects: 490
Study 31888783 — intervention group
Group type: COMPARATOR
Intervention: Placebo rinse
Number of subjects: 490
Study 29486353 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic + indocyanine green + 810 nm wavelength diode laser (antimicrobial photodynamic therapy group)
Number of subjects: 40
Study 29486353 — intervention group
Group type: COMPARATOR
Intervention: Antibiotic alone (control group)
Number of subjects: 40
Study 26836801 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion treatment daily for two weeks
Number of subjects: 200
Study 26836801 — intervention group
Group type: COMPARATOR
Intervention: Control without moxibustion
Number of subjects: 200
Study 25260838 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide 40 mg
Number of subjects: 198
Study 25260838 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide 60 mg
Number of subjects: 198
Study 25260838 — intervention group
Group type: COMPARATOR
Intervention: Active control (octreotide or lanreotide)
Number of subjects: 198
Study 25260838 — intervention group
Group type: COMPARATOR
Intervention: Active control
Number of subjects: 198
Study 23581697 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral testosterone undecanoate 240 mg/d
Number of subjects: 322
Study 23581697 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral testosterone undecanoate 160 mg/d
Number of subjects: 322
Study 23581697 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral testosterone undecanoate 80 mg/d, 160 mg/d, 240 mg/d
Number of subjects: 322
Study 23581697 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 322
Study 20082171 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone support intervention provided by trained senior peer counselors
Number of subjects: 107
Study 20082171 — intervention group
Group type: EXPERIMENTAL
Intervention: Training module and 20‐h course for senior peer counselors
Number of subjects: 107
Study 18972728 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture plus exercise group (electroacupuncture and infrared ray radiation plus passive exercise)
Number of subjects: 60
Study 18972728 — intervention group
Group type: COMPARATOR
Intervention: Exercise therapy group (active exercise after passive exercise)
Number of subjects: 60
Study 15746683 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe congenital anomalies and youngest gestational ages
Number of subjects: 1742
Study 15746683 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal age (< 18 and > 34 years)
Number of subjects: 1742
Study 15746683 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal delivery
Number of subjects: 1742
Study 15746683 — intervention group
Group type: EXPERIMENTAL
Intervention: Nontertiary hospital care
Number of subjects: 1742
Study 15746683 — intervention group
Group type: EXPERIMENTAL
Intervention: Malpresentation
Number of subjects: 1742
Study 15746683 — intervention group
Group type: EXPERIMENTAL
Intervention: Male gender
Number of subjects: 1742
Study 15746683 — intervention group
Group type: EXPERIMENTAL
Intervention: Small for gestational age
Number of subjects: 1742
Study 15746683 — intervention group
Group type: COMPARATOR
Intervention: Black race
Number of subjects: 1742
Study 15746683 — intervention group
Group type: COMPARATOR
Intervention: Preeclampsia
Number of subjects: 1742
Study 14671464 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocardiographic LVH present in 793 (8.3%) participants
Number of subjects: 9541
Study 14671464 — intervention group
Group type: COMPARATOR
Intervention: No ECG-LVH
Number of subjects: 9541
Study 10900676 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low fat diet (diet I)
Number of subjects: 37
Study 10900676 — intervention group
Group type: COMPARATOR
Intervention: Low fat diet (diet II)
Number of subjects: 37
Study 8953350 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-pharmacological nursing interventions
Number of subjects: 49
Study 8953350 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 49
Study 1727097 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiographic predictors (left ventricular dysfunction from 2-D echocardiograms)
Number of subjects: 568
Study 1727097 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiographic predictors (size of the left atrium from M-mode echocardiograms)
Number of subjects: 568
Study 1727097 — intervention group
Group type: COMPARATOR
Intervention: Echocardiographic results combined with clinical variables
Number of subjects: 568
Study 1727097 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiographic results
Number of subjects: 568
Study 6480875 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 Gm standard activated charcoal every 2 hours
Number of subjects: 8
Study 6480875 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 Gm PX‐21 activated charcoal every 2 hours
Number of subjects: 8
Study 6480875 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 Gm standard activated charcoal every 2 hours
Number of subjects: 8
Study 30938762 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide 0.5 mg
Number of subjects: 2432
Study 30938762 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide 1.0 mg
Number of subjects: 2432
Study 30938762 — intervention group
Group type: COMPARATOR
Intervention: Comparator (placebo or active comparator: sitagliptin 100 mg, exenatide extended release 2.0 mg)
Number of subjects: 2432
Study 28424190 — intervention group
Group type: EXPERIMENTAL
Intervention: Inulin (30 g/d)
Number of subjects: 16
Study 28424190 — intervention group
Group type: EXPERIMENTAL
Intervention: Propionate (6 g/d)
Number of subjects: 16
Study 28424190 — intervention group
Group type: COMPARATOR
Intervention: Cellulose (30 g/d)
Number of subjects: 16
Study 25154757 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyrone (575 mg, three times a day for 72 hr)
Number of subjects: 29